Isotretinoin exposure and pregnancy outcome: An observational study of the Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy

Archives of Gynecology and Obstetrics

Volumn 281, Issue 2, 2010, Pages 221-227

  Schaefer, Christof ^a   Meister, Reinhard ^b   Weber Schoendorfer, Corinna ^a  

^a Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy   (Germany)

^b BEUTH UNIVERSITY OF APPLIED SCIENCES   (Germany)

Author keywords

Acne; Contraception; Fetal outcome; Isotretinoin; Pregnancy; Pregnancy outcome; Retinoids; Teratogenicity

Indexed keywords

ISOTRETINOIN; DERMATOLOGICAL AGENT; TERATOGENIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CONTRACEPTION; CONTROLLED STUDY; DRUG CONTRAINDICATION; FACE ASYMMETRY; FEMALE; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; HEALTH EDUCATION; HEART VENTRICLE SEPTUM DEFECT; HIP DYSPLASIA; HUMAN; OBSERVATIONAL STUDY; PATENT FORAMEN OVALE; PREGNANCY OUTCOME; PREGNANCY TERMINATION; PRENATAL DRUG EXPOSURE; RISK ASSESSMENT; SELF CONCEPT; SEXUAL BEHAVIOR; SPONTANEOUS ABORTION; COHORT ANALYSIS; CONGENITAL MALFORMATION; GERMANY; INCIDENCE; MIDDLE AGED; NEWBORN; PREGNANCY; PROSPECTIVE STUDY;

ABNORMALITIES, DRUG-INDUCED; ADOLESCENT; ADULT; COHORT STUDIES; DERMATOLOGIC AGENTS; FEMALE; GERMANY; HUMANS; INCIDENCE; INFANT, NEWBORN; ISOTRETINOIN; MIDDLE AGED; PREGNANCY; PROSPECTIVE STUDIES; TERATOGENS; YOUNG ADULT;

EID: 77950356899     PISSN: 09320067     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00404-009-1112-2     Document Type: Article

References (25)

1. Abroms L, Maibach E, Lyon-Daniel K, Feldman SR (2006) What is the best approach to reducing birth defects associated with isotretinoin? PLoS Med 3:e483. doi:10.1371/journal.pmed.0030483 (Pubitemid 44875930)
2. Adams J (2004) The adverse effect proWle of neurobehavioral teratogens: retinoic acid. Birth Defects Res A 70:344
3. Adams J, Lammer E. (1991) Relationship between dysmorphology and neuropsychological functions in children exposed to isotretinoin (in utero). In: Fujii T, Boer GJ (eds) Functional neuroteratology of short term exposure to drugs. Teiko University Press, Tokyo, pp 159-168
4. Azoulay L, Oraichi D, Bérard A (2006) Patterns and utilization of isotretinoin from 1984 to 2003: is there need for concern? Eur J Clin Pharmacol 62:667-674. doi:10.1007/s00228-006-0151-x (Pubitemid 44127997)
5. Bérard A, Azoulay L, Koren G et al (2007) Isotretinoin, pregnancies, abortions and birth defects: a population-based perspective. Br J Clin Pharmacol 63:196-205. doi:10.1111/j.1365-2125.2006.02837.x (Pubitemid 46072106)
6. Dai WS, LaBraico JM, Stern RS (1992) Epidemiology of isotretinoin exposure during pregnancy. J Am Acad Dermatol 26:599-606. doi:10.1016/0190- 9622(92)70088-W
7. David M, Pachaly J, Vetter K (2006) Perinatal outcome in Berlin (Germany) among immigrants from Turkey. Arch Gynecol Obstet 274:271-278. doi:10.1007/s00404-006-0182-7 (Pubitemid 44127290)
8. Garcia-Bournissen F, Tsur L, Goldstein LH, Staroselsky A, Avner M, Asrar F, Berkovitch M, Straface G, Koren G, De Santis M (2008) Fetal exposure to isotretinoin-an international problem. Reprod Toxicol 25:124-128. doi:10.1016/j.reprotox.2007.10.005 (Pubitemid 50013715)
9. Holmes LB (1999) Need for inclusion and exclusion criteria for the structural abnormalities recorded in children born from exposed pregnancies. Teratology 64:79-82
10. Honein MA, Paulozzi LJ, Erickson JD (2001) Continued occurence of accutane exposed pregnancies. Teratology 64:142-147. doi:10.1002/tera.1057 (Pubitemid 32804006)
11. Johnson KA, Weber PA, Jones KL et al (2001) Selection bias in teratology information service pregnancy outcome studies. Teratology 64:79-82. doi:10.1002/tera.1048 (Pubitemid 32702472)
12. Lammer EJ, Chen DT, Hoar RM et al (1985) Retinoic acid embryopathy. N Engl J Med 313:837-841
13. Lammer EJ, Hayes AM, Schunior A et al (1988) Unusually high risk for adverse outcomes of pregnancy following fetal isotretinoin exposure. Am J Hum Genet 43:A 58
14. Martinez-Frias ML, Rodriguez-Pinilla E. (1999) The problems of using data from teratology information services (TIS) to identify putative teratogens. Teratology 60:54-55. doi:10.1002/(SICI) 1096-9926(199908)60:2<54::AID- TERA3>3.0.CO;2-3 (Pubitemid 29397191)
15. Merks JHM, van Karnebeek CDM, Caron HN, Hennekam RCM (2003) Phenotypic abnormalities: terminology and classiWcation. Am J Med Genet 123:211A-230A. doi:10.1002/ajmg.a.20249
16. Moerike S, Pantzar JT, De Sa D (2002) Temporal bone pathology in fetuses exposed to isotretinoin. Pediatr Dev Pathol 5:405-409. doi:10.1007/s10024-001- 0258-0
17. Moskop JC, Smith ML, De Ville K (1997) Ethical aspects of teratogenic medications: the case of isotretinoin. J Clin Ethics 8:264-278 (Pubitemid 127712738)
18. Nulman I, Berkovitch M, Klein J et al (1998) Steady-state pharmacokinetics of isotretinoin and ist 4-oxo metabolite: implications for fetal safety. J Clin Pharmacol 38:926-930 (Pubitemid 28482118)
19. Ornoy A, Mastroiacovo P (2000) More on data from teratogen information systems (TIS). Teratology 61:327-328. doi:10.1002/(SICI)1096-9926(200005)61: 5<327::AID-TERA2>3.0.CO;2-H (Pubitemid 30258816)
20. Raatikainen K, Heiskanen N, Heinonen S. (2007) Under-attending free antenatal care is associated with adverse pregnancy outcomes. BMC Public Health 7:268. doi:10.1186/1471-2458-7-268 (Pubitemid 350046015)
21. Rasmussen SA, Olney RS, Holmes LB, Lin AE, Keppler-Noreuil KM, Moore CA (2003) Guidelines for case classiWcation for the national birth defects prevention study. Birth Defects Res A 67:193-201. doi:10.1002/bdra.10012 (Pubitemid 37238061)
22. Robertson J, Polifka JE, Avner M et al (2005) A survey of pregnant women using isotretinoin. Birth Def Res A 73:881-887. doi:10.1002/bdra.20197 (Pubitemid 41739251)
23. Rosa FW (1983) Teratogenicity of isotretinoin. Lancet 2:513. doi:10.1016/S0140-6736(83)90538-X
24. Schaefer C, Arnoy A, Clementi M, Meister R, Weber-Schoendorfer C. (2008) Using observational cohort data for studying drug effects on pregnancy outcome-methodological considerations. Reprod Toxicol 26:36-41. doi:10.1016/j.reprotox.2008.05.064
25. Teratology Society (1991) Recommendations for isotretinoin use in women of child-bearing potential. Teratology 44:1-6. doi:10.1002/tera.1420440102